AS Latvijas Juras medicinas centrs

RISE:LJM1R Stock Report

Market Cap: €5.4m

AS Latvijas Juras medicinas centrs Past Earnings Performance

Past criteria checks 0/6

AS Latvijas Juras medicinas centrs's earnings have been declining at an average annual rate of -30.8%, while the Healthcare industry saw earnings growing at 10.1% annually. Revenues have been growing at an average rate of 8.2% per year.

Key information

-30.8%

Earnings growth rate

-30.8%

EPS growth rate

Healthcare Industry Growth9.7%
Revenue growth rate8.2%
Return on equity-12.4%
Net Margin-7.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How AS Latvijas Juras medicinas centrs makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

RISE:LJM1R Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2410-110
30 Jun 2410010
31 Mar 2410010
31 Dec 2310-110
30 Sep 2310010
30 Jun 239010
31 Mar 239010
31 Dec 2210110
30 Sep 2210110
30 Jun 2210110
31 Mar 2210110
31 Dec 219110
30 Sep 219110
30 Jun 218010
31 Mar 217010
31 Dec 207010
30 Sep 207010
30 Jun 207010
31 Mar 207010
31 Dec 197010
30 Sep 197010
30 Jun 197010
31 Mar 197010
31 Dec 187010
30 Sep 186010
30 Jun 186010
31 Mar 186010
31 Dec 176110
30 Sep 176010
30 Jun 176010
31 Mar 176010
31 Dec 166010
30 Sep 166010
30 Jun 166010
31 Mar 166010
31 Dec 156010
30 Sep 156110
30 Jun 156110
31 Mar 156110
31 Dec 145110
30 Sep 145000
30 Jun 145000
31 Mar 145000
31 Dec 135000

Quality Earnings: LJM1R is currently unprofitable.

Growing Profit Margin: LJM1R is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: LJM1R is unprofitable, and losses have increased over the past 5 years at a rate of 30.8% per year.

Accelerating Growth: Unable to compare LJM1R's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LJM1R is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (15.2%).


Return on Equity

High ROE: LJM1R has a negative Return on Equity (-12.36%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies